

New Patient Consent Form (FEMALE)

References:

- Gururani, K., Jose, J., & George, P. V. (2016). Testosterone as a marker of coronary artery disease severity in middle aged males. *Indian heart journal*, 68, S16-S20.
- Lucas-Herald, A. K., Alves-Lopes, R., Montezano, A. C., Ahmed, S. F., & Touyz, R. M. (2017). Genomic and non-genomic effects of androgens in the cardiovascular system: clinical implications. *Clinical Science*, 131(13), 1405-1418.
- Chistiakov, D. A., Myasoedova, V. A., Melnichenko, A. A., Grechko, A. V., & Orekhov, A. N. (2018). Role of androgens in cardiovascular pathology. *Vascular health and risk management*, 14, 283.
- Kay-Tee, K., & Chir, M. B. B. (2007). Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men. *Am Heart Association*, 116, 2694-701.
- Malkin, C. J., Pugh, P. J., Morris, P. D., Kerry, K. E., Jones, R. D., Jones, T. H., & Channer, K. S. (2004). Testosterone replacement in hypogonadal men with angina improves ischemic threshold and quality of life. *Heart*, 90(8), 871-876.
- Jones, T. Hugh, and Daniel M. Kelly. "Randomized controlled trials—mechanistic studies of testosterone and the cardiovascular system." *Asian journal of andrology* 20.2 (2018): 120
- Goodale, Travis, et al. "Testosterone and the Heart." *Methodist DeBakey cardiovascular journal* 13.2 (2017): 68
- Ohlander, S. J., Varghese, B., & Pastuszak, A. W. (2018). Erythrocytosis following testosterone therapy. *Sexual medicine reviews*, 6(1), 77-85.
- Mithoowani, S., Laureano, M., Crowther, M. A., & Hillis, C. M. (2020). Investigation and management of erythrocytosis. *CMAJ*, 192(32), E913-E918.
- Gordeuk, V. R., Key, N. S., & Prchal, J. T. (2019). Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis. *haematologica*, 104(4), 653-658.
- Carruthers M, Trinick TR, Wheeler MJ. The validity of androgen assays. *The Aging Male*. 2007; 10:165-172.
- Carruthers, M. (2008). The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action. *The journal of sexual medicine*, 5(4), 998-1012.
- Morgentaler, A. (2012). Goodbye androgen hypothesis, hello saturation model. *European urology*, 62(5), 765-767. 2005
- Morgentaler, A., Lipshultz, L. I., Bennett, R., Sweeney, M., Avila, D., & Khera, M. (2011). Testosterone therapy in men with untreated prostate cancer. *The Journal of urology*, 185(4), 1256-1261.
- Morgentaler, A., Zitzmann, M., Traish, A. M., Fox, A. W., Jones, T. H., Maggi, M., ... & Torres, L. O. (2016, July). Fundamental concepts regarding testosterone deficiency and treatment: international expert consensus resolutions. In *Mayo Clinic Proceedings* (Vol. 91, No. 7, pp. 881-896).

EvexiPEL HRT Consent Form (FEMALE)

References:

- Carruthers, M. (2008). The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action. *The journal of sexual medicine*, 5(4), 998-1012.
- Carruthers, M. (2008). The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action. *The journal of sexual medicine*, 5(4), 998-1012.

Bachmann, G., Bancroft, J., Braunstein, G., Burger, H., Davis, S., Dennerstein, L., ... & Traish, A. (2002). Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. *Fertility and sterility*, 77(4), 660-665.

Shufelt, C. L., & Braunstein, G. D. (2009). Safety of testosterone use in women. *Maturitas*, 63(1), 63-66.

Panay, N., & Fenton, A. (2009). The role of testosterone in women.

Maclaran, K., & Panay, N. (2012). The safety of postmenopausal testosterone therapy. *Women's Health*, 8(3), 263-275.

EvexiPEL HRT Consent Form (MALE)

References:

Gururani, K., Jose, J., & George, P. V. (2016). Testosterone as a marker of coronary artery disease severity in middle aged males. *Indian heart journal*, 68, S16-S20.

Lucas-Herald, A. K., Alves-Lopes, R., Montezano, A. C., Ahmed, S. F., & Touyz, R. M. (2017). Genomic and non-genomic effects of androgens in the cardiovascular system: clinical implications. *Clinical Science*, 131(13), 1405-1418.

Chistiakov, D. A., Myasoedova, V. A., Melnichenko, A. A., Grechko, A. V., & Orekhov, A. N. (2018). Role of androgens in cardiovascular pathology. *Vascular health and risk management*, 14, 283.

Kay-Tee, K., & Chir, M. B. B. (2007). Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men. *Am Heart Association*, 116, 2694-701.

Malkin, C. J., Pugh, P. J., Morris, P. D., Kerry, K. E., Jones, R. D., Jones, T. H., & Channer, K. S. (2004). Testosterone replacement in hypogonadal men with angina improves ischemic threshold and quality of life. *Heart*, 90(8), 871-876.

Jones, T. Hugh, and Daniel M. Kelly. "Randomized controlled trials—mechanistic studies of testosterone and the cardiovascular system." *Asian journal of andrology* 20.2 (2018): 120

Goodale, Travis, et al. "Testosterone and the Heart." *Methodist DeBakey cardiovascular journal* 13.2 (2017): 68

Ohlander, S. J., Varghese, B., & Pastuszak, A. W. (2018). Erythrocytosis following testosterone therapy. *Sexual medicine reviews*, 6(1), 77-85.

Mithoowani, S., Laureano, M., Crowther, M. A., & Hillis, C. M. (2020). Investigation and management of erythrocytosis. *CMAJ*, 192(32), E913-E918.

Gordeuk, V. R., Key, N. S., & Prchal, J. T. (2019). Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis. *haematologica*, 104(4), 653-658.

Carruthers M, Trinick TR, Wheeler MJ. The validity of androgen assays. *The Aging Male*. 2007; 10:165-172.

Carruthers, M. (2008). The paradox dividing testosterone deficiency symptoms and androgen assays: a closer look at the cellular and molecular mechanisms of androgen action. *The journal of sexual medicine*, 5(4), 998-1012.

Morgentaler, A. (2012). Goodbye androgen hypothesis, hello saturation model. *European urology*, 62(5), 765-767. 2005

Morgentaler, A., Lipshultz, L. I., Bennett, R., Sweeney, M., Avila, D., & Khera, M. (2011). Testosterone therapy in men with untreated prostate cancer. *The Journal of urology*, 185(4), 1256-1261.

Morgentaler, A., Zitzmann, M., Traish, A. M., Fox, A. W., Jones, T. H., Maggi, M., ... & Torres, L. O. (2016, July). Fundamental concepts regarding testosterone deficiency and treatment: international expert consensus resolutions. In *Mayo Clinic Proceedings* (Vol. 91, No. 7, pp. 881-896).